compounded semaglutide ban 🚨 FDA Moves to Permanently Shut Down GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these is compounded tirzepatide banned The

Glucagon receptor activation affects intestinal motility and alters bile acid flux through the enterohepatic circulation (i.e

Patients undergoing tirzepatide therapy commonly experience: Improved blood pressure: reductions in systolic and diastolic blood pressure have been observed across tirzepatide clinical trials Better cholesterol profiles: reductions in LDL and triglycerides, with improvements in HDL Improved blood glucose regulation: tirzepatide significantly improves insulin sensitivity and reduces fasting glucose, even in patients without diabetes Reduction in waist circumference: visceral fat reduction, which is directly associated with reduced cardiovascular and metabolic risk Preservation of lean muscle mass: unlike traditional caloric restriction, which often results in 2530% of weight loss coming from muscle, tirzepatide promotes preferential fat loss Potential hormonal benefits: emerging evidence suggests that fat mass reduction lowers aromatase activity, which may support healthier testosterone-to-estrogen balance For patients managing multiple metabolic conditions simultaneously, GLP-1/GIP weight loss therapy represents an opportunity to address root causes, rather than individual symptoms, through a single medically supervised intervention

Weight Watchers has launched a new program called WeightWatchers Clinic

Do not increase the dosage too quickly, and do not start the medication with higher doses

subcutaneous) and frequencies (daily vs

But the mechanisms differ slightly because tirzepatide acts on two receptors (GLP-1 and GIP) while semaglutide acts on one (GLP-1 only)